← Back to Screener
Cartesian Therapeutics, Inc. Common Stock (RNAC)
Price$6.38
Favorite Metrics
Price vs S&P 500 (26W)-45.43%
Price vs S&P 500 (4W)-15.75%
Market Capitalization$158.79M
All Metrics
Book Value / Share (Quarterly)$0.03
P/TBV (Annual)2.30x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-70.66%
Cash Flow / Share (Quarterly)$-3.05
Price vs S&P 500 (YTD)-19.56%
Net Profit Margin (TTM)-4658.63%
EPS (TTM)$-5.02
10-Day Avg Trading Volume0.16M
EPS Excl Extra (TTM)$-5.02
Revenue Growth (5Y)-29.96%
EPS (Annual)$-5.02
ROI (Annual)29.46%
Net Profit Margin (5Y Avg)-1140.15%
Cash / Share (Quarterly)$4.81
Revenue Growth QoQ (YoY)1129.87%
ROA (Last FY)-43.96%
Revenue Growth TTM (YoY)-92.96%
EBITD / Share (TTM)$-5.49
ROE (5Y Avg)-185.49%
Operating Margin (TTM)-5127.10%
Cash Flow / Share (Annual)$-3.05
P/B Ratio211.16x
P/B Ratio (Quarterly)512.19x
Net Income / Employee (Annual)$-2
EV / Revenue (TTM)12.03x
Net Interest Coverage (TTM)-0.62x
ROA (TTM)-35.53%
EPS Incl Extra (Annual)$-5.02
Current Ratio (Annual)8.65x
Quick Ratio (Quarterly)8.45x
3-Month Avg Trading Volume0.20M
52-Week Price Return-53.92%
EV / Free Cash Flow (Annual)3.02x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.39
P/S Ratio (Annual)56.77x
Asset Turnover (Annual)0.01x
52-Week High$15.57
Operating Margin (5Y Avg)-1112.90%
EPS Excl Extra (Annual)$-5.02
CapEx CAGR (5Y)46.26%
Tangible BV CAGR (5Y)12.61%
26-Week Price Return-41.45%
Quick Ratio (Annual)8.45x
13-Week Price Return-17.61%
Total Debt / Equity (Annual)0.28x
Current Ratio (Quarterly)8.65x
Enterprise Value$33.65
Revenue / Share Growth (5Y)-53.44%
Asset Turnover (TTM)0.01x
Book Value / Share Growth (5Y)-23.36%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-4987.31%
Cash / Share (Annual)$4.81
3-Month Return Std Dev92.35%
Net Income / Employee (TTM)$-2
ROE (Last FY)37.71%
Net Interest Coverage (Annual)-0.64x
EPS Basic Excl Extra (Annual)$-5.02
P/FCF (TTM)21.19x
Receivables Turnover (TTM)2.82x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-5.02
Receivables Turnover (Annual)2.82x
ROI (TTM)-3215.82%
P/S Ratio (TTM)56.77x
Pretax Margin (5Y Avg)-1216.71%
Revenue / Share (Annual)$0.11
Tangible BV / Share (Annual)$0.61
Price vs S&P 500 (52W)-83.75%
Year-to-Date Return-16.92%
5-Day Price Return-3.07%
EPS Normalized (Annual)$-5.02
ROA (5Y Avg)-25.70%
Net Profit Margin (Annual)-4658.63%
Month-to-Date Return-2.60%
Cash Flow / Share (TTM)$-0.23
EBITD / Share (Annual)$-5.51
Operating Margin (Annual)-5127.10%
LT Debt / Equity (Annual)0.19x
ROI (5Y Avg)-74.06%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-5.02
P/TBV (Quarterly)3.57x
P/B Ratio (Annual)2.17x
Pretax Margin (TTM)-4987.31%
Book Value / Share (Annual)$0.61
Price vs S&P 500 (13W)-18.29%
Beta0.62x
P/FCF (Annual)4.66x
Revenue / Share (TTM)$0.11
ROE (TTM)-3215.82%
52-Week Low$5.60
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.13
4.13
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
RNACCartesian Therapeutics, Inc. Common Stock | 56.77x | -92.96% | — | — | $6.38 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Cartesian Therapeutics is a clinical-stage biopharmaceutical company developing mRNA-based therapies to induce immune tolerance. The company's ImmTOR platform uses proprietary manufacturing and cellular engineering technology to mitigate unwanted immune responses, particularly in autoimmune and transplant-related conditions. This approach represents a novel mechanism for treating conditions where immune suppression needs to be targeted rather than systemic.